Table_6_Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer.xlsx
Breast cancer is the most prevalent type of malignancy in women worldwide. Taxanes (paclitaxel and docetaxel) are widely applied as first-line chemotherapeutic agents, while the therapeutic effect is seriously limited by the development of drug resistance. In the present study, we screened out several miRNAs dysregulated in taxanes-resistant breast cancer samples and confirmed that two miRNAs (miR-335-5p and let-7c-5p) played a major role in cell proliferation, apoptosis, and chemo-resistance. In addition, the weighted gene co-expression network analysis (WGCNA) for potential target genes of miR-335-5p and let-7c-5p identified three hub genes (CXCL9, CCR7, and SOCS1) with a positive relationship to taxanes-sensitivity. Further, target relationships between miR-335-5p and CXCL9, let-7c-5p and CCR7/SOCS1 were confirmed by dual-luciferase reporter assays. Importantly, the regulatory functions of CXCL9, CCR7, and SOCS1 on proliferation and chemoresistance were validated. In conclusion, our study shed light on clinical theragnostic relationships between miR-335-5p/CXCL9, let-7c-5p/CCR7/SOCS1 axes, and taxanes-resistance in breast cancer.
History
References
- https://doi.org//10.3322/caac.21590
- https://doi.org//10.1016/S0140-6736(16)31795-0
- https://doi.org//10.1136/bmj.e2718
- https://doi.org//10.6004/jnccn.2019.0009
- https://doi.org//10.1016/S0140-6736(16)32419-9
- https://doi.org//10.1038/nrc3599
- https://doi.org//10.1007/164_2017_20
- https://doi.org//10.1146/annurev.med.53.082901.103929
- https://doi.org//10.1038/nrclinonc.2013.67
- https://doi.org//10.2174/0929867324666170623093445
- https://doi.org//10.1016/j.tcb.2018.05.001
- https://doi.org//10.1007/978-1-4939-3542-0_25
- https://doi.org//10.1016/j.ctrv.2012.02.011
- https://doi.org//10.2165/00003088-200544040-00002
- https://doi.org//10.1038/bjc.2016.203
- https://doi.org//10.1038/s41467-019-09312-9
- https://doi.org//10.1038/nrc2803
- https://doi.org//10.1016/j.ccell.2015.05.009
- https://doi.org//10.1002/ijc.32559
- https://doi.org//10.1158/0008-5472.CAN-17-3871
- https://doi.org//10.1038/nrg1379
- https://doi.org//10.1016/S0092-8674(03)00428-8
- https://doi.org//10.1016/j.eururo.2019.06.010
- https://doi.org//10.1038/s41467-019-11826-1
- https://doi.org//10.1038/ncomms15870
- https://doi.org//10.1101/gad.292318.116
- https://doi.org//10.1016/j.mam.2019.10.007
- https://doi.org//10.1111/bjh.15547
- https://doi.org//10.1016/S1470-2045(17)30621-6
- https://doi.org//10.1158/0008-5472.CAN-14-1140
- https://doi.org//10.18632/oncotarget.3065
- https://doi.org//10.1016/j.neo.2018.12.005
- https://doi.org//10.1159/000354521
- https://doi.org//10.1038/s41419-017-0211-4
- https://doi.org//10.1038/nrg.2016.134
- https://doi.org//10.1186/s13148-017-0413-8
- https://doi.org//10.1002/hep.29586
- https://doi.org//10.1002/cam4.1682
- https://doi.org//10.1002/1873-3468.12538
- https://doi.org//10.1074/jbc.M111.278705
- https://doi.org//10.1186/s13046-019-1190-3
- https://doi.org//10.1038/s41419-018-0286-6
- https://doi.org//10.1016/j.cytogfr.2013.03.001
- https://doi.org//10.1186/s12943-017-0629-4
- https://doi.org//10.1016/j.cell.2013.01.053
- https://doi.org//10.1038/nature13862
- https://doi.org//10.1016/j.bbadis.2017.10.033
- https://doi.org//10.1016/j.immuni.2019.05.013
- https://doi.org//10.1002/ijc.25236
- https://doi.org//10.1002/path.2448
- https://doi.org//10.1038/bjc.2016.172
- https://doi.org//10.1016/j.ctrv.2017.11.007
- https://doi.org//10.1016/j.ccell.2017.11.019
- https://doi.org//10.1038/nbt.4086
- https://doi.org//10.18632/oncotarget.17982
- https://doi.org//10.1038/s41419-018-1010-2
- https://doi.org//10.1007/s11033-019-04993-3
- https://doi.org//10.1158/2326-6066.CIR-18-0651
- https://doi.org//10.1038/s41467-018-04013-1
- https://doi.org//10.1016/j.molcel.2009.09.044
- https://doi.org//10.1128/MCB.01446-14
- https://doi.org//10.1016/j.cyto.2016.01.015
- https://doi.org//10.1038/onc.2015.485
- https://doi.org//10.18632/oncotarget.3737
CC BY 4.0